Rochelle Bagatell

10.1k total citations · 2 hit papers
148 papers, 7.0k citations indexed

About

Rochelle Bagatell is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Rochelle Bagatell has authored 148 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Neurology, 60 papers in Molecular Biology and 40 papers in Oncology. Recurrent topics in Rochelle Bagatell's work include Neuroblastoma Research and Treatments (78 papers), Cancer therapeutics and mechanisms (40 papers) and Cancer, Hypoxia, and Metabolism (31 papers). Rochelle Bagatell is often cited by papers focused on Neuroblastoma Research and Treatments (78 papers), Cancer therapeutics and mechanisms (40 papers) and Cancer, Hypoxia, and Metabolism (31 papers). Rochelle Bagatell collaborates with scholars based in United States, Canada and Spain. Rochelle Bagatell's co-authors include Susan L. Cohn, John M. Maris, Michael D. Hogarty, Luke Whitesell, Wendy B. London, Julie R. Park, Garrett M. Brodeur, Arlene Naranjo, Gillian Paine-Murrieta and Charles W. Taylor and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rochelle Bagatell

139 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuroblastoma

2007 1.6k citations John M. Maris, Michael D. Hogarty et al. profile →
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

2021 249 citations Meredith S. Irwin, Arlene Naranjo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Rochelle Bagatell

Since Specialization

Citations

This map shows the geographic impact of Rochelle Bagatell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rochelle Bagatell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rochelle Bagatell more than expected).

Fields of papers citing papers by Rochelle Bagatell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rochelle Bagatell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rochelle Bagatell. The network helps show where Rochelle Bagatell may publish in the future.

Co-authorship network of co-authors of Rochelle Bagatell

This figure shows the co-authorship network connecting the top 25 collaborators of Rochelle Bagatell. A scholar is included among the top collaborators of Rochelle Bagatell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rochelle Bagatell. Rochelle Bagatell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors 2025 ·Cancer Medicine ·David S. Shulman, Kieuhoa T. Vo, Frank M. Balis, Holly Lindsay, Rochelle Bagatell, Andrew E. Place, Susan Chi, Suzanne Shusterman, (unknown), Jeffrey T. Czaplinski, (unknown), Pei‐Chi Kao, Wendy B. London, Steven G. DuBois	0
2	Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study 2025 ·Journal of Clinical Oncology ·Esther R. Berko, Arlene Naranjo, (unknown), Samantha N. McNulty, Kateryna Krytska, Todd E. Druley, Kristin Zelley, (unknown), Lulu Chen, (unknown), Meredith S. Irwin, Rochelle Bagatell, John M. Maris, C. Patrick Reynolds, Steven G. DuBois, Julie R. Park, Yaël P. Mossé	1
3	A 2035 Clinical Research Vision and Roadmap for High‐Risk Neuroblastoma 2025 ·Pediatric Blood & Cancer ·Lucas Moreno, Steven G. DuBois, Nick Bird, (unknown), (unknown), Andrew D.J. Pearson, Maja Beck‐Popovic, Rochelle Bagatell	1
4	Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group 2024 ·SHILAP Revista de lepidopterología ·Elizabeth Sokol, (unknown), Navin Pinto, Susan G. Kreissman, (unknown), Julie R. Park, Rochelle Bagatell, Arlene Naranjo, Steven G. DuBois	1
5	A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. 2024 ·Journal of Clinical Oncology ·Ami V. Desai, Arlene Naranjo, (unknown), Kelly C. Goldsmith, Meaghan Granger, Lisa J. States, (unknown), (unknown), Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian	1
6	Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study. 2024 ·Journal of Clinical Oncology ·David S. Shulman, Kelly Klega, Nan Chen, (unknown), (unknown), Edwin Choy, Thomas F. Cash, Kris Ann P. Schultz, Leo Mascarenhas, Rochelle Bagatell, Brian Turpin, Bhuvana A. Setty, (unknown), Douglas S. Hawkins, Michael W. Bishop, Avanthi Tayi Shah, Luke Maese, Wendy B. London, Steven G. DuBois, Brian D. Crompton	1
7	SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES). 2024 ·Journal of Clinical Oncology ·Patrick J. Grohar, Karla V. Ballman, (unknown), Leo Mascarenhas, John Glod, (unknown), (unknown), Steven G. DuBois, Robert G. Maki, Brian D. Crompton, William D. Figg, Rochelle Bagatell, Theodore W. Laetsch, Mark S. Diamond, Fariba Navid, Ryan D. Roberts, Brigitte C. Widemann, Denise K. Reinke, Rashmi Chugh	5
8	Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531 2024 ·Pediatric Blood & Cancer ·(unknown), Howard M. Katzenstein, Arlene Naranjo, Sheena C. Tenney, Lulu Chen, Wendy B. London, Michael H. Handler, Mary Lou Schmidt, Hiroyuki Shimada, Michael D. Hogarty, (unknown), Julie R. Park, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Clare J. Twist	0
9	Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report 2023 ·Clinical Cancer Research ·Navin Pinto, Arlene Naranjo, Xiangming Ding, Fan F. Zhang, Emily Hibbitts, Rebekah Kennedy, (unknown), (unknown), David W. Craig, Zarko Manojlovic, Michael D. Hogarty, Susan G. Kreissman, Rochelle Bagatell, Meredith S. Irwin, Julie R. Park, Shahab Asgharzadeh	8
10	Children's Oncology Group's 2023 blueprint for research: Neuroblastoma 2023 ·Pediatric Blood & Cancer ·Rochelle Bagatell, Steven G. DuBois, Arlene Naranjo, (unknown), Kelly C. Goldsmith, Julie R. Park, Meredith S. Irwin	11
11	Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study 2023 ·Cancer ·Erica C. Kaye, Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N. Baker, Susan L. Cohn, Lisa Diller, Julia Glade Bender, Meaghan Granger, Araz Marachelian, Julie R. Park, Abby R. Rosenberg, Suzanne Shusterman, Clare J. Twist, Jennifer W. Mack	6
12	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 2021 ·Clinical Cancer Research ·Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm A. Smith, Barry L. Shulkin, Marguerite T. Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park, Paul M. Sondel	132
13	Neuroblastoma 2021 ·Pediatric Blood & Cancer ·Christine H. Chung, Tom Boterberg, John T. Lucas, Joseph Panoff, Dominique Valteau‐Couanet, Barbara Hero, Rochelle Bagatell, Christine E. Hill‐Kayser	88
14	A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study 2021 ·Pediatric Blood & Cancer ·Brian Weiss, Gregory A. Yanik, Arlene Naranjo, Fan F. Zhang, Wendy Fitzgerald, Barry L. Shulkin, Marguerite T. Parisi, Heidi V. Russell, Stephan A. Grupp, Luke Pater, Peter Mattei, Yaël P. Mossé, Hollie Lai, Jason A. Jarzembowski, Hiroyuki Shimada, Judith G. Villablanca, Roger Giller, Rochelle Bagatell, Julie R. Park, Katherine K. Matthay	23
15	Trends in conditional survival and predictors of late death in neuroblastoma 2020 ·Pediatric Blood & Cancer ·(unknown), Kevin Campbell, Rochelle Bagatell, Steven G. DuBois	5
16	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events 2019 ·Pediatric Blood & Cancer ·Tamara P. Miller, Brian T. Fisher, Kelly Getz, (unknown), Hanieh Razzaghi, Alix E. Seif, Rochelle Bagatell, Peter C. Adamson, Richard Aplenc	39
17	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project 2019 ·Pediatric Blood & Cancer ·Kevin Campbell, Derek Shyr, Rochelle Bagatell, Matthias Fischer, Akira Nakagawara, Adela Cañete, Garrett M. Brodeur, Katherine K. Matthay, Wendy B. London, Steven G. DuBois	25
18	VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma 2017 ·Pediatric Blood & Cancer ·Bhuvana A. Setty, Joseph Stanek, Leo Mascarenhas, (unknown), Rochelle Bagatell, (unknown), (unknown), (unknown), Abha A. Gupta	27
19	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group 2017 ·Cancer ·Kevin Campbell, Julie M. Gastier‐Foster, (unknown), Arlene Naranjo, Collin Van Ryn, Rochelle Bagatell, Katherine K. Matthay, Wendy B. London, Meredith S. Irwin, (unknown), Meaghan Granger, Michael D. Hogarty, Julie R. Park, Steven G. DuBois	95
20	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy 2005 ·Journal of Clinical Oncology ·Rochelle Bagatell, (unknown), Wendy B. London, Susan L. Cohn, A. Thomas Look, Garrett M. Brodeur, Christopher Frantz, Vijay Joshi, Paul S. Thorner, Pejaver V. Rao, Robert P. Castleberry, Laura C. Bowman	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact